There are currently 1493 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
NCT06750185
Recruiting
This is a first-in-human (FIH), open-label, multiple-site, dose escalation study which will evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Advanced Solid Tumor
Register for Updates
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter to Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
NCT05134012
Recruiting
This a Phase 3, prospective, open-label, multicenter study of \[15-O\]-H2O injection for PET imaging of subjects with suspected CAD. Approximately 182 evaluable participants with suspected CAD referred for testing will be included in the study at approximately 10 study sites in the United States and Europe. Approximately 215 participants will be enrolled to account for an estimated 15% drop-out rate. Screening assessments will occur prior to enrollment to confirm eligibility. All participants wi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Coronary Artery Disease
Register for Updates
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
NCT04620239
Recruiting
This is a phase 3, open label, single arm study of padeliporfin in the treatment of Upper Tract Urothelial Carcinoma (UTUC). The ENLIGHTED study will recruit patients with low-grade non-invasive upper tract urothelial carcinoma in either the kidney or the ureter. Patients will be treated with padeliporfin VTP in two phases: an Induction Treatment Phase and a Maintenance Treatment Phase and will be followed up for up to an additional 48 months in the long term (non intervention) follow up phase w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Texas Southwestern, Dallas, Texas
Conditions: Transitional Cell Cancer of Renal Pelvis and Ureter
Register for Updates
Study to Evaluate the Safety and Effectiveness of the enVista® Beyond (EY) EDF Intraocular Lens in Subjects Undergoing Cataract Extraction
NCT06333015
Recruiting
This research study is evaluating the safety and efficacy (performance) of the Bausch + Lomb enVista Beyond Hydrophobic Acrylic Extended Depth of Focus Intraocular Lens (IOL) in subjects who receive this IOL in both eyes.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
02/04/2025
Locations: Site 103, Dallas, Texas
Conditions: Cataract
Register for Updates
Cycled Phototherapy
NCT03927833
Recruiting
Cycled phototherapy (PT) is likely to increase survival over that with continuous PT among extremely premature infants (\< 750 g BW or \<27 weeks GA).
Gender:
ALL
Ages:
Between 22 weeks and 27 weeks
Trial Updated:
02/04/2025
Locations: University of Texas Southwestern Medical Center at Dallas, Dallas, Texas
Conditions: Hyper Bilirubinemia, Premature Infant
Register for Updates
Dosing of Overground Robotic Gait Training with Functional Outcomes and Neuroplasticity After Spinal Cord Injury
NCT05218447
Recruiting
The DOOR SCI project examines dosing effects of robotic gait training (RGT) and transcranial magnetic stimulation (TMS) initiated during inpatient rehabilitation and continued through early outpatient rehabilitation
Gender:
ALL
Ages:
Between 16 years and 85 years
Trial Updated:
02/04/2025
Locations: Baylor Scott & White Institute for Rehabilitation, Dallas, Texas
Conditions: Spinal Cord Injuries
Register for Updates
Food Supplementation Delivered Conditionally vs Not Among Patients With Heart Failure
NCT06115369
Recruiting
The current study proposes to investigate if the provision of healthy food can improve outcomes following discharge after HF hospitalization. To investigate this in an efficient and pragmatic manner, a 2x2 factorial randomized control trial design will be utilized to simultaneously investigate two separate, important food-related questions: * Does the provision of 90 days of either medically-tailored meals or fresh produce boxes improve 90-day patient outcomes among those with HF relative to a... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/04/2025
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Heart Failure
Register for Updates
Blood Purification for the Treatment of Pathogen Associated Shock
NCT05011656
Recruiting
This study is a multi-center, randomized controlled feasibility trial to evaluate the initial safety and efficacy of a novel extracorporeal blood purification (EBP) therapy in critically ill patients with pathogen associated shock across 15 U.S. sites. Adults (18 years old and older) admitted to the ICU with all of the following: • Pathogen associated shock defined as: * The need for vasopressors to maintain mean arterial pressure (MAP) ≥ 65 mmHg despite adequate fluid resuscitation * Presence... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Septic Shock
Register for Updates
Study of PYX-201 in Solid Tumors
NCT05720117
Recruiting
The primary objectives of this study are to determine the recommended dose(s) of PYX-201 for participants with relapsed/refractory (R/R) solid tumors, and to determine the objective response rate (ORR) in participants treated with PYX-201 as a single agent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: NEXT Dallas, Dallas, Texas
Conditions: Solid Tumor, Advanced Solid Tumor
Register for Updates
Study of Selinexor in Combination with Ruxolitinib in Myelofibrosis
NCT04562389
Recruiting
This is a global, multicenter, 2-part study to evaluate the efficacy and safety of selinexor plus ruxolitinib in JAK inhibitor (JAKi) treatment-naïve myelofibrosis (MF) participants. The study will be conducted in two phases: Phase 1 (open-label) and Phase 3 (double-blind). Phase 1 (enrollment completed) was an open-label evaluation of the safety and recommended Phase 2 dose (RP2D) of selinexor in combination with ruxolitinib and included a dose escalation using a standard 3+3 design (Phase 1a)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Texas Oncology, Dallas, Texas
Conditions: Myelofibrosis
Register for Updates
Brain Health on College Campuses
NCT06724887
Recruiting
Center for BrainHealth is beginning a one-year pilot with local college campuses investigating the impact of (i) brain health assessment and training tools delivered through the online BrainHealth Platform and (ii) in-person educational brain health workshops delivered to college students and faculty/staff, with the overarching goal to better understand how to promote brain-healthier campuses (i.e., reflecting generally positive function across cognitive, social, emotional, and lifestyle domains... Read More
Gender:
ALL
Ages:
Between 18 years and 110 years
Trial Updated:
02/03/2025
Locations: Dallas College, Dallas, Texas
Conditions: Health Behavior, Life Style, Healthy
Register for Updates
SELUTION 4 De Novo Small Vessel IDE Trial
NCT05946629
Recruiting
Prospective, randomized controlled, single-blind, multicenter, clinical trial to demonstrate the safety and efficacy of the SELUTION SLR 014 PTCA DEB for treatment of de novo lesions in small coronary vessels, defined as reference vessel diameter (RVD) of 2.00 mm to 2.75 mm, in support of a pre-market approval (PMA) application to the United States (US) FDA. The Study will enroll up to 910 randomized subjects, up to 30 subjects in a parallel angiographic substudy, and up to 20 subjects in a par... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/03/2025
Locations: Baylor Scott and White - Dallas, Dallas, Texas
Conditions: Coronary Artery Disease
Register for Updates